Proactive Investors - Run By Investors For Investors

ChemioCare USA appoints three new members to board with eye toward going public in 2019

CEO says having three independent directors is an important step to position the private company for a successful initial public offering
doctor cuts gauze
ChemioCare transforms chemotherapy induced nausea and vomiting with a transdermal patch

Privately held ChemioCare USA Inc. has appointed three new key members to its board and management team as it looks toward going public in the first half of 2019.

The pharmaceutical company, based in New York, specializes in neutralizing chemotherapy-induced nausea and vomiting through its own transdermal patch technology.

Andy Resnick joins the company as chief manufacturing officer. The former president and COO of Tapemark brings 30-years of experience to transdermal development and manufacturing. He currently sits on the board of advisors for Hydra-Flex chemical dispensing systems.

READ: Callitas Health, ChemioCare and Pressure BioSciences make a splash at Proactive Investors forum

Hemal Shah will take on the role of Health Economics and Outcomes Advisor. Shah has over 20 years of experience in health economics and outcomes research. She is the former senior vice president of Medical Affairs, Healthcare Quality, Policy and Outcomes at Optimer Pharmaceuticals and executive director at HEOR at Boehringer Ingelheim.

Finally, Eric Baum joins ChemioCare as a director. Baum has worked for Fortune 50 companies and was managing director of Acquis Consulting Group and managing director and co-founder of Solidea Capital. He brings 15 years of experience to ChemioCare's board.

“The appointments are valuable to us as we are at the stage where we need to position ourselves to be ready for an IPO.  Each one of our new members has specific skills that will help us,” ChemioCare Chairman and CEO Pedro Lichtinger told Proactive Investors. Lichtinger added that the company aims to list on the Nasdaq in the first half of 2019. 

“The strength and depth of our pipeline and rapid development pace are being made possible by the addition of best in class support," the CEO said in a statement.

"Andy Rensink will lead our transition from the preclinical setting into Manufacturing, and Hemal Shah is adding incredible insights into the value our products will create by addressing the significant unmet medical need in the CINV setting," he said, adding that the board would also be strengthened by Baum's appointment.

--Updated to add date of IPO, quote from ChemioCare CEO, corrects spelling of Shah's first name--

View full CHMIO profile View Profile

ChemioCare Timeline

Related Articles

lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use